Why Teva Paid $40.5 Billion for Allergan’s Generic Business

Israel’s Teva Pharmaceuticals’ acquisition of Allergan’s global generic pharma business is part of its strategic game plan of making Teva both a generic giant and a creator of original drugs.

The Joseph H. Lauder Institute
256 South 37th street
2nd Floor
Philadelphia, PA 19104-6330